02:44 , Feb 28, 2019 |  BC Week In Review  |  Clinical News

Lynparza notches first in POLO trial of pancreatic cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) announced the first positive data for a targeted agent in a molecularly defined subgroup of patients with metastatic pancreatic cancer. On Feb. 26, the...
23:05 , Feb 1, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Fiscal 2Q; (C) During trading hours in Europe; premarket on U.S. exchange Company Date...
23:40 , Jan 25, 2019 |  BioCentury  |  Politics, Policy & Law

101 problems with patent eligibility

The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...
21:03 , Jan 15, 2019 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A peptide that selectively activates the GABBR1a-splicing isoform of GABBR1 could be useful for probing the role of the isoform in Alzheimer’s disease (AD), epilepsy, schizophrenia and other neurological diseases. In vitro...
21:11 , Dec 31, 2018 |  BC Extra  |  Company News

Management tracks: Myriad co-founder Meldrum passes away

Peter Meldrum, co-founder and former CEO of Myriad Genetics Inc. (NASDAQ:MYGN), passed away on Dec. 20 at the age of 71. Meldrum retired from the molecular diagnostics company in 2015, when Mark Capone became president...
19:26 , Dec 28, 2018 |  BC Extra  |  Company News

Management tracks: Schwartz steps down as Kadmon chairman

Kadmon Holdings Inc. (NYSE:KDMN) said Bart Schwartz is stepping down as chairman, citing Schwartz’s increasing responsibilities at his charitable commitments. The inflammatory and fibrotic disease company is seeking a successor. CytoDyn Inc. (OTCBB:CYDY) hired Nitya...
23:33 , Nov 2, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least nine profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 1Q; (B) Fiscal 4Q Company Date Pre/post mkt 3Q18 EPS est 3Q17 EPS Expected chg Bausch...
16:04 , Oct 25, 2018 |  BC Innovations  |  Translation in Brief

Classifying BRCA1 mutations

University of Washington researchers have characterized the clinical consequences of nearly 4,000 variants in the tumor suppressor gene BRCA1 using saturation genome editing. The results provide interpretation of variants with previously uncertain significance and will...
18:10 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

After three deals, FDA approval, talazoparib joins PARP party

FDA approved Talzenna talazoparib from Pfizer Inc. (NYSE:PFE) to treat germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, making it the second PARP inhibitor approved for the indication. The approval comes well ahead of...
22:50 , Oct 16, 2018 |  BC Extra  |  Company News

After three deals, FDA approval talazoparib joins PARP party

FDA approved Talzenna talazoparib from Pfizer Inc. (NYSE:PFE) to treat germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, making it the second PARP inhibitor approved for the indication. The approval comes well ahead of...